MX2021015300A - Métodos de producción de un anticuerpo anti-¿4¿7. - Google Patents

Métodos de producción de un anticuerpo anti-¿4¿7.

Info

Publication number
MX2021015300A
MX2021015300A MX2021015300A MX2021015300A MX2021015300A MX 2021015300 A MX2021015300 A MX 2021015300A MX 2021015300 A MX2021015300 A MX 2021015300A MX 2021015300 A MX2021015300 A MX 2021015300A MX 2021015300 A MX2021015300 A MX 2021015300A
Authority
MX
Mexico
Prior art keywords
antibody
methods
vedolizumab
production
integrin antibody
Prior art date
Application number
MX2021015300A
Other languages
English (en)
Spanish (es)
Inventor
Debra Ameli
Susan R Carter
Michael E Dolan
Nicole Hilo
Amitava Kundu
Amy Miller
George Parks
Olga Paley
Paras Bhatia
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2021015300A publication Critical patent/MX2021015300A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021015300A 2019-06-10 2020-06-10 Métodos de producción de un anticuerpo anti-¿4¿7. MX2021015300A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859494P 2019-06-10 2019-06-10
PCT/US2020/037059 WO2020252069A1 (en) 2019-06-10 2020-06-10 METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY

Publications (1)

Publication Number Publication Date
MX2021015300A true MX2021015300A (es) 2022-02-03

Family

ID=73781728

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021015300A MX2021015300A (es) 2019-06-10 2020-06-10 Métodos de producción de un anticuerpo anti-¿4¿7.
MX2026003883A MX2026003883A (es) 2019-06-10 2021-12-10 Metodos de produccion de un anticuerpo anti-a4?7
MX2026003881A MX2026003881A (es) 2019-06-10 2021-12-10 Metodos de produccion de un anticuerpo anti-a4?7

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2026003883A MX2026003883A (es) 2019-06-10 2021-12-10 Metodos de produccion de un anticuerpo anti-a4?7
MX2026003881A MX2026003881A (es) 2019-06-10 2021-12-10 Metodos de produccion de un anticuerpo anti-a4?7

Country Status (14)

Country Link
US (1) US20220267449A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980466A4 (cg-RX-API-DMAC7.html)
JP (2) JP7624414B2 (cg-RX-API-DMAC7.html)
CN (3) CN121736106A (cg-RX-API-DMAC7.html)
AR (1) AR119270A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020290943A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024897A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143167A1 (cg-RX-API-DMAC7.html)
IL (1) IL288825A (cg-RX-API-DMAC7.html)
MA (1) MA56129A (cg-RX-API-DMAC7.html)
MX (3) MX2021015300A (cg-RX-API-DMAC7.html)
PL (1) PL439809A1 (cg-RX-API-DMAC7.html)
TW (1) TW202112818A (cg-RX-API-DMAC7.html)
WO (1) WO2020252069A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292146A (zh) 2018-04-10 2021-01-29 雷迪博士实验室有限公司 治疗性抗体的稳定的制剂
US12024561B2 (en) * 2018-04-10 2024-07-02 Dr. Reddy's Laboratories Limited Stable antibody formulation
TW202112819A (zh) * 2019-06-10 2021-04-01 美商千禧製藥公司 用於抗體製備之細胞培養方法及組合物
US20240376209A1 (en) * 2021-07-29 2024-11-14 Dr. Reddy’S Laboratories Limited Method To Control High Molecular Weight Aggregates In An Antibody Composition
EP4380948A4 (en) * 2021-08-05 2025-07-16 Dr Reddys Laboratories Ltd METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY
US20240400610A1 (en) * 2021-09-03 2024-12-05 Dr. Reddy's Laboratories Limited Method to obtain a purified antibody composition
WO2024233992A2 (en) * 2023-05-11 2024-11-14 Trophogen, Inc. Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
EP3116891B1 (en) * 2014-03-10 2020-02-12 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
JP2025063035A (ja) 2025-04-15
CN121736106A (zh) 2026-03-27
US20220267449A1 (en) 2022-08-25
TW202112818A (zh) 2021-04-01
MX2026003881A (es) 2026-05-04
EP3980466A4 (en) 2023-06-07
EP3980466A1 (en) 2022-04-13
CN114375307B (zh) 2025-12-05
CA3143167A1 (en) 2020-12-17
MA56129A (fr) 2022-04-13
MX2026003883A (es) 2026-05-04
AR119270A1 (es) 2021-12-09
JP2022536486A (ja) 2022-08-17
CN114375307A (zh) 2022-04-19
JP7624414B2 (ja) 2025-01-30
JP7877431B2 (ja) 2026-06-22
IL288825A (en) 2022-02-01
AU2020290943A1 (en) 2022-02-03
WO2020252069A1 (en) 2020-12-17
CN119859188A (zh) 2025-04-22
BR112021024897A2 (pt) 2022-01-18
PL439809A1 (pl) 2022-12-05

Similar Documents

Publication Publication Date Title
PL439809A1 (pl) Metody wytwarzania przeciwciała anty-alfa4beta7
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
BR112021024848A2 (pt) Métodos de purificação de anticorpos e composições dos mesmos
BR112021025359A2 (pt) Composições de proteína anti-vegf e métodos para a produção das mesmas
ATE526017T1 (de) Abscheidung von polyelektrolyten und reinigung von antikörpern
van der Linden et al. Anti-citrullinated histone monoclonal antibody CIT-013, a dual action therapeutic for neutrophil extracellular trap-associated autoimmune diseases
MX354592B (es) Metodo para aumentar el rendimiento de las plantas y composiciones que mejoran el rendimiento.
MY168961A (en) Antibodies to pcsk9 and uses thereof
EA201790342A1 (ru) Антитела к trem2 и способы их применения
TN2012000555A1 (en) Antibodies to human gdf8
MX2018002068A (es) Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes.
SG169359A1 (en) A method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
RS59557B1 (sr) Tau antitela i njihova upotreba
JOP20220255A1 (ar) أجسام tau المضادة لـ phf المضاد واستخداماتها
MX2020010724A (es) Metodos para preparar composiciones proteicas estables.
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
MX2021003567A (es) Métodos y composiciones para aumentar la expresión de proteínas y/o tratar un trastorno por haploinsuficiencia.
IN2014CH00378A (cg-RX-API-DMAC7.html)
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
MX2017009253A (es) Anticuerpos antiglicoproteina y usos de los mismos.
ZA202006216B (en) Antibodies targeting glycoprotein vi
MX2022008442A (es) Metodos para disminuir impurezas de procesos de manufacturacion de proteinas recombinantes.
ES2673518T3 (es) Métodos para modificar las tasas de producción de proteínas